Rezultati

Apremilast, a cAMP phosphodiesterase‐4 inhibitor, demonstrates anti‐inflammatory activity <i>in vitro</i> and in a model of psoriasis od PH Schafer, Andrew Parton, Ajeet Kumar Gandhi, Lori Capone, Mary Beth Adams, Lei Wu, JB Bartlett, MA Loveland, Amos Gilhar, Y‐F Cheung, GS Baillie, Miles D. Houslay, H‐W Man, G. Müller, DI Stirling

Polni tekst Polni tekst

Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast od Melinda Gooderham, Kim Papp

Polni tekst Polni tekst

Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors od Miguel Pérez‐Aso, M. Carmen Montesinos, Aránzazu Mediero, Tuere Wilder, Peter Schäfer, Bruce N. Cronstein

Polni tekst

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and S... od Kim Papp, Kristian Reich, Craig L. Leonardi, Leon Kircik, Sergio Chimenti, Richard Langley, ChiaChi Hu, Randall M. Stevens, Robert M. Day, Kenneth B. Gordon, Neil J. Korman, C.E.M. Griffiths

Polni tekst

Efficacy and Safety of Systemic Long-Term Treatments for Moderate-to-Severe Psoriasis: A Systematic Review and Meta-Analysis od Alexander Nast, Anja Jacobs, Stefanie Rosumeck, Ricardo Niklas Werner

Polni tekst Polni tekst

A Review of phosphodiesterase-inhibition and the potential role for phosphodiesterase 4-inhibitors in clinical dermatology od Farah Moustafa, Steven R. Feldman

Polni tekst Polni tekst

The Pharmacodynamic Impact of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, on Circulating Levels of Inflammatory Biomarkers in Patients with Psoriatic Arthritis: Substudy Res... od Peter Schäfer, Peng Chen, Lorraine Fang, Andrew Wang, Rajesh Chopra

Polni tekst Polni tekst

New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast od Andrew C. Palfreeman, McNamee, Fiona E. McCann

Polni tekst Polni tekst

Phosphodiesterase 4 Inhibition in the Treatment of Psoriasis, Psoriatic Arthritis and Other Chronic Inflammatory Diseases od Miriam Wittmann, Philip Helliwell

Polni tekst Polni tekst

Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity od Peter Schäfer, Anastasia Parton, Lori Capone, Dorota Cedzik, Helen Brady, Jilly F. Evans, Hon‐Wah Man, George W. Muller, David Stirling, Rajesh Chopra

Polni tekst

Apremilast for Behçet’s Syndrome — A Phase 2, Placebo-Controlled Study od Gülen Hatemi, Melike Melikoğlu, Recep Tunç, Cengiz Korkmaz, Banu Öztürk, Cem Mat, Peter A. Merkel, Kenneth Calamia, Ziqi Liu, Lilia Pineda, Randall M. Stevens, Hasan Yazıcı, Yusuf Yazıcı

Polni tekst Polni tekst

Can the anti‐inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking? od M A Giembycz

Polni tekst

Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population‐based Multinational Assessment of Psoriasis and Psoriatic Arthritis surve... od P.C.M. van de Kerkhof, Kristian Reich, Arthur Kavanaugh, H. Bachelez, Juliet N. Barker, Giampiero Girolomoni, Richard Langley, C. Paul, L. Puig, Mark Lebwohl

Polni tekst

Advances in treating psoriasis od Katharina Belge, Jürgen Brück, Kamran Ghoreschi

Polni tekst Polni tekst

Patient-reported Health-related Quality of Life with Apremilast for Psoriatic Arthritis: A Phase II, Randomized, Controlled Study od Vibeke Strand, Georg Schett, ChiaChi Hu, Randall M. Stevens

Polni tekst Polni tekst

Phosphodiesterase 4-targeted treatments for autoimmune diseases od Neal Kumar, Ari M. Goldminz, Noori Kim, Alice B. Gottlieb

Polni tekst Polni tekst

Psoriatic arthritis therapy: NSAIDs and traditional DMARDs od Peter Nash, Daniel O. Clegg

Polni tekst Polni tekst

Longterm (52-week) Results of a Phase III Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis od Arthur Kavanaugh, Philip J. Mease, Juan J. Gómez‐Reino, Adewale O. Adebajo, Jürgen Wollenhaupt, Dafna D Gladman, Marla Hochfeld, Lichen L. Teng, Georg Schett, Éric Lespessailles, Stephen Hall

Polni tekst Polni tekst

Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled tri... od C. Paul, Jennifer Clay Cather, Melinda Gooderham, Yves Poulin, Ulrich Mrowietz, Carlos Montilla, J. Crowley, ChiaChi Hu, R.M. Stevens, Kara N. Shah, R. M. Day, Giampiero Girolomoni, A.B. Gottlieb

Polni tekst Polni tekst

Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases od Georg Schett, Victor S. Sloan, Randall M. Stevens, Peter Schäfer

Polni tekst Polni tekst